Explanipedia

44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC) Open

Pedro C. Barata, Brian I. Rini, Toni Choueri, Sumanta K. Pal, Philippe Barthélémy , et al. · 2025

Background Tivo is a potent and highly selective VEGFR inhibitor designed to optimize VEGF blockade and minimize off-target toxicities. In TiNivo-2, patients with mRCC who had previous exposure to ICI, were randomized to receive study trea…

13Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005) Open

Thomas Powles, Guillermo de Velasco, Toni Choueri, Gregory Chen, Ying Xiao , et al. · 2025

Background Belzutifan significantly prolonged progression-free survival vs. everolimus in the phase 3 LS-005 trial (NCT04195750) among patients with advanced RCC who had previously received immune checkpoint and antiangiogenic therapies. Q…

11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis Open

Koral Shah, Paulo Gustavo Bergerot, Daniela V. Castro, Benjamin Mercier, Elizabeth Nally , et al. · 2025

Background Understanding how health-related quality of life (HRQOL) concerns vary by disease stage is essential for developing patient-reported outcome measures (PROMs) that reflect the lived experiences of individuals with renal cell carc…

The Safety Profile of Belzutifan in Renal Tumors: Real-World Data from a Tertiary Academic Center Open

Aaron Winer, Paulo Siqueira do Amaral, Elizabeth Ryan, Morgan Lambrecht, Chiu-Lan Chen , et al. · 2025

BACKGROUND Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects o…

Long-term Safety and Efficacy of Belzutifan in Von Hippel–Lindau Syndrome: A VHL Coordinating Care Center Experience Open

Paulo Siqueira do Amaral, Ricardo Fonseca, Breanne Reisen, Aaron Winer, Gabriel Berlingieri Polho , et al. · 2025

Von Hippel–Lindau (VHL) disease is a rare inherited syndrome characterized by benign and malignant neoplasms. Belzutifan, a HIF-2α inhib-itor, was approved for the treatment of VHL-associated neoplasms. As a first-in-class agent, understan…

Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma Open

Cristiane Decat Bergerot, David Cella, Paulo Gustavo Bergerot, Daniela V. Castro, Benjamin Mercier , et al. · 2025

We successfully developed item subsets of the FKSI-23 questionnaire that address the multifaceted impact of localized and metastatic RCC on patients' HRQOL. These two clinical settings required distinct tools for optimal measurement of HRQ…

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial Open

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Tom Waddell , et al. · 2025

At the first interim analysis of the phase 3 KEYNOTE-426 trial, first-line pembrolizumab plus axitinib showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) over sunitinib for advanced ren…

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma Open

Brian I. Rini, Laurence Albigès, Xiaobin Tang, Hartmut Koeppen, Axel Bex , et al. · 2025

The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials Open

Elaine Chang, Haley Gittleman, Chi Song, Erik Bloomquist, Laura S. Fernandes , et al. · 2025

Background Retrospective analyses of studies of IO–containing combinations for advanced renal cell carcinoma (RCC) suggest that depth of response is associated with overall survival but have methodological limitations. We investigated the …

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma Open

Kathryn E. Beckermann, Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson , et al. · 2025

Background Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept competitively binds GAS6 limiting inter…

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors Open

Paulo Siqueira Amaral, Kathryn E. Beckermann, Jennifer Gordetsky, Sam S. Chang, Daniel Joyce , et al. · 2025

Background and objective Cytoreductive nephrectomy following immune checkpoint blockade (ICB) in metastatic renal cell carcinoma remains controversial, with limited data on its clinical and pathological outcomes. This study evaluated the o…

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia Open

Hsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, Satoshi Tamada, Nobuaki Matsubara , et al. · 2025

Background The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in …

640 A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in patients with relapsed or refractory clear cell renal cell carcinoma Open

Kathryn E. Beckermann, Brian I. Rini, Blake T. Aftab, Helen Budworth, Francesco Galimi , et al. · 2024

P183 Nivolumab Plus Ipilimumab (NIVO+IPI) vs Sunitinib (SUN) for first-line treatment of advanced Renal Cell Carcinoma (aRCC): Efficacy across number of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors with 8-year follow-up from the phase 3 CheckMate 214 trial Open

B. Escudier, R.J. Motzer, Nizar M. Tannir, Brian I. Rini, Camillo Porta , et al. · 2024

42 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study Open

Laurence Albigès, Toni K. Choueiri, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto , et al. · 2024

Background Belzutifan monotherapy is approved for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a PD-(L)1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) based on…

8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial Open

Michael B. Atkins, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri , et al. · 2024

Background First-line nivolumab plus ipilimumab (NIVO+IPI) has provided substantial long-term survival benefits over sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in CheckMate 214. With a median follow-up of 8 years…

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial Open

Nizar M. Tannir, Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri , et al. · 2024

Supplementary Table S2 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open